CMA costs dispute goes to Supreme Court

The UK's Supreme Court has permitted Flynn Pharma and Pfizer to appeal against a ruling that required the drug companies to pay the costs of their successful appeal against a decision by the UK's Competition and Markets Authority.


Get unlimited access to all Global Competition Review content